Neurogene stock a new Overweight at J.P. Morgan (NGNE:NASDAQ)
· seekingalpha.com
Neurogene (NGNE) stock gains as J.P. Morgan starts coverage with an Overweight rating and a $60 target, citing its lead program for Rett syndrome. Read more here.
J.P. Morgan has initiated coverage of gene therapy developer Neurogene (NGNE) with an Overweight recommendation, highlighting its lead program NGN-401 targeting...